Explore the words cloud of the SEQUOIA-DD project. It provides you a very rough idea of what is the project "SEQUOIA-DD" about.
The following table provides information about the project.
SYNAPSE INFORMATION LIMITED
|Coordinator Country||United Kingdom [UK]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
|Duration (year-month-day)||from 2016-09-01 to 2017-02-28|
Take a look of project's partnership.
|1||SYNAPSE INFORMATION LIMITED||UK (BIRMINGHAM)||coordinator||50˙000.00|
Synapse Information (UK) have developed a novel semantic web technology, SEQUOIA – Semantic Query of Information Assets – allowing users to rapidly question > 100 disparate data assets in a code-free spreadsheet environment. Having proved the core platform functionality within the financial sector, Synapse now seek to apply SEQUOIA to the field of drug discovery R&D.
New drugs are required urgently to treat cancers & other rare/neurological diseases. However, costs and timescales of drug development are huge due to high failure rates. A principle barrier is the lack of real time comparison of disparate datasets, which can identify causal correlations behind reactions throughout the R&D process. Building on the prototype kernel solution, SEQUOIA targets the many high performance silos of public online drug R&D data, enabling all researchers to semantically probe these ontologies against internal R&D. Synapse therefore aim to catalyse a strategic 10 - 100× productivity gain during the discovery phase to disrupt the €5.5 billion/yr drug discovery software market.
The overall project aims to: fulfil the further technical developments required to transfer SEQUOIA into priority sectors within drug R&D; initiate the technical and commercial partnerships with key stakeholders in the pharmaceutical industry; validate performance through extended field trials; establish regulatory compliance; deliver compatibility with key user data environments; and optimise a developed product.
The proposed Phase 1 feasibility study seeks to address these requirements through: delivery of an elaborated business plan; prioritised EU market entry strategy; analysis of market-held data assets, technical development roadmap; engagement of key stakeholders in the pharmaceutical industry; supply chain initiation; development of IP strategy and value model; as well as regulatory and legal roadmaps for the final phase of developments and exploitation.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SEQUOIA-DD" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SEQUOIA-DD" are provided by the European Opendata Portal: CORDIS opendata.
In-Memory Computing and Artificial Intelligence Platform for Building Next Generation Enterprise SoftwareRead More
Osmotic Wearable Bolus Injector (oWBI) for viscous drug deliveryRead More
ScanVid - One-Click Integrated Access to Product-related Digital ContentRead More